DUBLIN, March 5, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/5pbz3g/future_prospects) have announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma.
Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
3. Introduction
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Key Leading Countries
9. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Key Vendor Analysis
17. Other Reports in this Series
Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/5pbz3g/future_prospects
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article